Medistim launches clinical study on TTFM and HFUS in Vascular surgery
Medistim announces the launch of the PATENT study, an open, prospective, multicenter trial aimed at evaluating the immediate clinical benefits and long-term prognostic value of intraoperative completion control using transit time flow measurement (TTFM) and high-frequency ultrasound (HFUS) imaging. The study focuses on patients undergoing bypass surgery for Critical Limb Threatening Ischemia (CLTI) below the knee. Medistim is a global market leader in intraoperative quality assessment and surgical guidance in Cardiac surgery, serving 37% of the worldwide coronary artery bypass graft (CABG) market, which comprises over 700,000 procedures annually. The company continues to expand its presence in this field. As part of its growth strategy, Medistim aims to establish an equally strong position in Vascular surgery, with peripheral bypass surgery identified as a particularly promising target segment.
